Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1900 Target Snapshot

Aldo-keto reductase family 1 member B1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,035Compounds
224Assays
8Approved Drugs
1,211.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Aldo-keto reductase family 1 member B1 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P15121. Start with diabetes mellitus, then reuse UniProt P15121 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetes mellitus, then reuse UniProt P15121 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
diabetes mellitus

Aldo-keto reductase family 1 member B1 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include TOLRESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aldo-keto reductase family 1 member B1 as ChEMBL target CHEMBL1900, mapped to UniProt P15121. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aldo-keto reductase family 1 member B1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1900
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P15121
Aldo-keto reductase family 1 member B1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Aldo-keto reductase family 1 member B1 is the right protein anchor across sources, using UniProt P15121 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetes mellitus is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAldo-keto reductase family 1 member B1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP15121
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAldo-keto reductase family 1 member B1
UniProt AccessionP15121
Component TypeProtein
Sequence Length316 aa

Aldo-keto reductase family 1 member B1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Aldo-keto reductase family 1 member B1, mapped to UniProt P15121. Sequence length is 316 aa.

Mapped IDP15121
Review nameAldo-keto reductase family 1 member B1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Aldo-keto reductase family 1 member B1 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugTOLRESTAT
Late clinical Phase III
diabetic retinopathy
1 linked drug · 1 direct · 1 efficacy
Linked drugSORBINIL
Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugEPALRESTAT
Clinical signal Phase II
Charcot-Marie-Tooth disease
1 linked drug · 1 direct · 1 efficacy
Linked drugEPALRESTAT
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugCAFICRESTAT
Clinical signal Phase I
diabetic cardiomyopathy
1 linked drug · 1 direct · 1 efficacy
Linked drugCAFICRESTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include TOLRESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
5
Phase III
20
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,174.0
KI36.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2260162 9.89 IC50 0.13 Preclinical
CHEMBL2260155 9.82 IC50 0.15 Preclinical
CHEMBL1645381 9.77 IC50 0.17 Preclinical
CHEMBL2260152 9.59 IC50 0.26 Preclinical
CHEMBL1645384 9.55 IC50 0.28 Preclinical
CHEMBL2260158 9.31 IC50 0.49 Preclinical
CHEMBL2260153 9.18 IC50 0.66 Preclinical
CHEMBL2260163 9.09 IC50 0.82 Preclinical
CHEMBL240725 9.08 IC50 0.84 Preclinical
CHEMBL20207 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

125
5.0
122
5.5
160
6.0
161
6.5
145
7.0
114
7.5
65
8.0
15
8.5
9
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

EPALRESTAT
CHEMBL56337
Approved 1992
Properties Compare Identifier
TOLRESTAT
CHEMBL436
Approved 1989
Properties Compare Identifier
SULINDAC
CHEMBL15770
Approved 1978
Properties Compare Identifier
Assay Landscape

Assay Landscape

224
Total Assays
898
Tested Compounds
3
Assay Types
Binding — 219 assays, 898 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 140 387 6.3
assay format 69 463 6.5
cell-based format 7 46 6.7
tissue-based format 2 1 6.5
organism-based format 1 1 6.8
ADME — 3 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 5.5
microsome format 1 0 —
single protein format 1 10 4.7
Functional — 2 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 2 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine